Non-ASH Meetings

Non-ASH Meetings

On-site interview with presenters at meetings and summits in the hematology/oncology arena


Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

Amrita Y. Krishnan, MD, shares the promising preliminary results from a phase I/II study of the triplet regimen ixazomib, pomalidomide, and dexamethasone in patients...

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL

Noelle V. Frey, MD, discusses the challenges of balancing the promises of chimeric antigen receptor T-cell therapy with its side effects in patients with...

David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line...

With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate...

Current Issue

October 2021, Volume 7, Issue 12

This issue tells the long story of drug shortages, demystifies transfusion services, and more.

Block title